XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Operations - Unaudited - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue $ 0 $ 0 $ 0 $ 2,009
Operating expenses:        
Research and development 2,824 3,055 11,457 8,393
General and administrative 2,544 2,634 9,338 9,813
Total operating expenses 5,368 5,689 20,795 18,206
Operating loss (5,368) (5,689) (20,795) (16,197)
Interest income 131 150 384 200
Interest expense (4) (8) (6) (9)
Loss before income taxes and noncontrolling interest (8,540) (5,468) (21,525) (18,783)
Income tax provision 0 0 0 200
Net loss before noncontrolling interest (8,540) (5,468) (21,525) (18,983)
Less: net loss attributable to noncontrolling interest (1,886) (1,207) (4,753) (4,564)
Net loss attributable to vTv Therapeutics Inc. (6,654) (4,261) (16,772) (14,419)
Net loss attributable to vTv Therapeutics Inc. common shareholders (6,654) (4,261) (16,772) (14,419)
Nonrelated Party        
Operating expenses:        
Other income (expense) (3,640) 403 (1,514) (2,998)
Related Party        
Operating expenses:        
Other income (expense) $ 341 $ (324) $ 406 $ 221
Class A Common Stock        
Operating expenses:        
Net loss per share of vTv Therapeutics Inc. Class A common stock, basic (in usd per share) $ (0.08) $ (0.05) $ (0.21) $ (0.20)
Net loss per share of vTv Therapeutics Inc. Class A common stock, diluted (in usd per share) $ (0.08) $ (0.05) $ (0.21) $ (0.20)
Weighted-average number of vTv Therapeutics Inc. Class A common stock, basic (in shares) 81,483,600 80,490,121 81,483,600 72,649,531
Weighted-average number of vTv Therapeutics Inc. Class A common stock, diluted (in shares) 81,483,600 80,490,121 81,483,600 72,649,531